Novartis Canada is pleased to announce that Health Canada has granted a Notice of Compliance for Fabhalta® (iptacopan ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full year ended December 31, 2024 and ...

References 1. Risitano AM, Han B, Kulasekararaj AG, et al. Oral iptacopan monotherapy leads to long-term improvements in patient (Pt)-reported health-related quality of life (HRQoL) and ...

SAR-443809 is under clinical development by Sanofi and currently in Phase I for Paroxysmal Nocturnal Hemoglobinuria. According to GlobalData, Phase I drugs for Paroxysmal Nocturnal Hemoglobinuria have ...

A combination treatment has shown promise for treating a rare blood disease, according to a clinical trial published in the ...

Buying Alexion remains a “fantastic acquisition” for AstraZeneca, the Big Pharma’s CEO has said, even as the company takes a ...

If there were an official hierarchy of qualities that dividend seekers should consider before investing in a stock, a company ...

Despite the discontinuations, CEO Pascal Soriot said AstraZeneca’s December 2020 acquisition of Alexion was a “fantastic” ...

Research analysts at StockNews.com started coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Get Free Report) in a report released on Thursday. The brokerage set a “sell” rating on the ...

The phase 3 trial was carried out in patients with paroxysmal nocturnal hemoglobinuria (PNH), one if the indications on Soliris' label, and showed that there was no difference between the ...

Jeremy Crosby at B&B Sports in Hutchinson has been on the phone with an important customer lately, trying to help make a wish come true. He and Tyson Karsky, a 17-year-old from Clinton, went ...